Ergocalciferol Supplements Improve Vitamin D Deficiency, Not Anemia
Six-months of supplementation has no impact on epoetin utilization in HD patients with low 25(OH)D.
(HealthDay News) -- For patients on hemodialysis with serum 25-hydroxy vitamin D (25[OH]D) <30 ng/mL, ergocalciferol supplementation improves 25(OH)D levels but has no impact on epoetin utilization, according to a study published online in the Journal of the American Society of Nephrology.
Dana C. Miskulin, MD, from the Tufts Medical Center in Boston, and colleagues conducted a 6-month randomized trial to examine the effects of supplementation with ergocalciferol on epoetin utilization in 276 patients on hemodialysis with serum 25(OH)D <30 ng/mL.
The researchers observed an increase in the mean serum 25(OH)D from 16.0 ± 5.9 ng/mL at baseline to 39.2 ± 14.9 ng/mL in the ergocalciferol arm, compared with no change in the placebo arm. Over 6 months there was no significant change in epoetin dose in the ergocalciferol or placebo arms (geometric mean rate, 0.98 versus 0.99), and no difference across arms (P = 0.78). No changes were seen in either arm in serum calcium, phosphorus, intact parathyroid hormone, or C-reactive protein levels, or in cinacalcet use, phosphate binder, or calcitriol dose. There was no between-arm difference in the rates of all-cause, cardiovascular, and infection-related hospitalizations.
"In conclusion, 6 months of supplementation with ergocalciferol increased serum 25(OH)D levels in patients on hemodialysis with vitamin D insufficiency or deficiency, but had no effect on epoetin utilization or secondary biochemical and clinical outcomes," the authors write.
All authors disclosed financial ties to Dialysis Clinic Inc.